| P2093 | author name string | William McPheat | |
| | Carl Whatling | |
| | Margareta Herslöf | |
| P2860 | cites work | Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation | Q24290820 |
| | In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity | Q28143839 |
| | International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors | Q28180458 |
| | Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis | Q28205296 |
| | Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis | Q28236868 |
| | Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma | Q36573399 |
| | New anti-inflammatory agents to reduce atherosclerosis | Q36576558 |
| | Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses | Q36591942 |
| | Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways | Q36647303 |
| | Atherosclerosis: disease biology affecting the coronary vasculature | Q36684354 |
| | Assessment of unstable atherosclerosis in mice | Q36749103 |
| | Plaque rupture in humans and mice | Q36749108 |
| | Biosynthesis and metabolism of leukotrienes | Q36876280 |
| | 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation | Q38303459 |
| | A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction | Q40156481 |
| | Modulators of leukotriene biosynthesis and receptor activation | Q40933620 |
| | Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005 | Q41861535 |
| | Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia | Q43415395 |
| | Lipid mediator class switching during acute inflammation: signals in resolution. | Q43655799 |
| | Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies | Q43863070 |
| | Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice | Q44079670 |
| | Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase | Q44555577 |
| | The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. | Q45025551 |
| | Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation | Q45236245 |
| | A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction | Q46155185 |
| | Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial | Q46484359 |
| | Association between 5-lipoxygenase expression and plaque instability in humans | Q46525384 |
| | Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate | Q46633982 |
| | Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice | Q47445076 |
| | Cell biology of the 5-lipoxygenase pathway | Q47908090 |
| | Differential leukotriene constrictor responses in human atherosclerotic coronary arteries | Q47924147 |
| | Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach | Q48495227 |
| | The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke | Q56944340 |
| | Leukotriene B4production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction | Q57258178 |
| | ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study | Q58885883 |
| | 5-Lipoxygenase-activating protein (FLAP) | Q28287966 |
| | Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice | Q28299579 |
| | Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist | Q28319336 |
| | Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects | Q28378483 |
| | Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung | Q28565050 |
| | Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms | Q28579031 |
| | Inflammation, atherosclerosis, and coronary artery disease | Q29547232 |
| | In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity | Q30312104 |
| | Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population | Q33938710 |
| | Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents | Q34224474 |
| | Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain | Q34274379 |
| | Antileukotrienes in clinical development for asthma | Q34481959 |
| | Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial | Q34501729 |
| | Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. | Q34570881 |
| | Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability | Q34601356 |
| | Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast | Q34622997 |
| | Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo | Q34791616 |
| | Designing therapeutically effective 5-lipoxygenase inhibitors | Q35431877 |
| | From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. | Q35552554 |
| | From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. | Q35558849 |
| | Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005 | Q35563505 |
| | Leukotriene A4 hydrolase as a target for cancer prevention and therapy | Q35768488 |
| | Inflammatory resolution: new opportunities for drug discovery | Q35770168 |
| | An update of the leukotriene modulators for the treatment of asthma | Q35814442 |
| | The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues | Q35835017 |
| | Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses | Q35841909 |
| | Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase | Q35871340 |
| | Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis | Q35953220 |
| | Development of 5-lipoxygenase inhibitors--lessons from cellular enzyme regulation | Q36134241 |
| | Leukotriene modifiers as potential therapeutics for cardiovascular disease | Q36205826 |
| | The forgotten majority: unfinished business in cardiovascular risk reduction | Q36274303 |
| | Disruption of TGF-β signaling in T cells accelerates atherosclerosis | Q36524547 |
| | Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses | Q36573372 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| | circulatory system | Q11068 |
| P304 | page(s) | 1879-1893 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field | |
| P478 | volume | 16 | |